Anzeige
Mehr »
Login
Samstag, 05.04.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Ist das der Durchbruch für den KI-Biotech-Geheimtipp?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 858560 | ISIN: US5324571083 | Ticker-Symbol: LLY
Xetra
04.04.25
17:35 Uhr
683,30 Euro
-38,80
-5,37 %
Branche
Pharma
Aktienmarkt
S&P 500
S&P 100
1-Jahres-Chart
ELI LILLY AND COMPANY Chart 1 Jahr
5-Tage-Chart
ELI LILLY AND COMPANY 5-Tage-Chart
RealtimeGeldBriefZeit
660,00661,5004.04.
672,80676,6004.04.
PR Newswire
404 Leser
Artikel bewerten:
(2)

Oblique Therapeutics AB: Oblique Therapeutics has entered a research collaboration agreement with Eli Lilly and Company to apply the AbiProt® technology to generate antibodies to a high-value target

Finanznachrichten News

STOCKHOLM, Aug. 22, 2024 /PRNewswire/ -- Oblique Therapeutics, a leading biotechnology company specialising in the development of new drug candidates, is pleased to announce that they have entered into a research collaboration agreement with Eli Lilly and Company (Lilly) to apply the AbiProt® technology to generate antibodies to a high-value target. This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties.

Under this collaboration agreement, Oblique will partner with Lilly Catalyze360-ExploR&D, a pillar of external innovation at Lilly that brings enterprise learning, scientific know-how, and best-in-class research and development capabilities to accelerate partner science.

The parties already have an existing agreement in place (signed in November 2023) and this agreement expands the collaboration between the companies to a second high-value target.

"We are delighted to expand the collaboration between our companies and together create new science to address the unmet medical need in severe diseases. This collaboration with Lilly is of great importance to us and will further strengthen our position within the antibody discovery space," says Christer Nordstedt, CEO at Oblique Therapeutics.

About Oblique Therapeutics

Oblique Therapeutics is a biotechnology company that focuses on developing new therapeutic methods for treating severe illnesses, especially in the area of pain management and also for other conditions. The company uses pioneering technology and innovative research methods to discover and develop new antibody-based drug candidates.

Contact: Christer Nordstedt (Christer.Nordstedt@obliquet.com)

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/oblique-therapeutics-ab/r/oblique-therapeutics-has-entered-a-research-collaboration-agreement-with-eli-lilly-and-company-to-ap,c4027460

The following files are available for download:

https://mb.cision.com/Main/16877/4027460/2957423.pdf

Press Release OBT-Lilly_eng

Cision View original content:https://www.prnewswire.co.uk/news-releases/oblique-therapeutics-has-entered-a-research-collaboration-agreement-with-eli-lilly-and-company-to-apply-the-abiprot-technology-to-generate-antibodies-to-a-high-value-target-302228552.html

© 2024 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.